News

Demonstrating Excellence in Outcomes and Culture

OJEMDA™ (tovorafenib) Now Available from Onco360 for the Treatment of Patients Six Months of Age and Older with Relapsed or Refractory Pediatric Low-Grade Glioma (LGG) Harboring a BRAF Fusion or Rearrangement, or BRAF V600 Mutation

News

Stay up to date with the latest innovations, company updates, and industry insights as we work to advance health and wellness for all.